Valiant Organics Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹304 Cr +93.6% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
VO

Valiant Organics Ltd

Q3 FY26Chemicals & Petrochemicals

Valiant Organics Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹159Cr
−15% YoY
+1.3% QoQ
Net profit
₹4Cr
−20% YoY
−33.3% QoQ
Margin
8%
0 pp YoY
−5 pp QoQ

Based on Valiant Organics Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹411
Market cap₹1.2K Cr
P/E23.7

The short version

Q3-FY26 Consolidated Revenue from Operations: INR 1,593 Mn, down 14.8% YoY (Q3-FY25: INR 1,869 Mn) - Q3-FY26 Standalone Revenue from Operations: INR 1,591 Mn, down 14.9% YoY (Q3-FY25: INR 1,869 Mn) - Key chemistry sales volumes (Metric Tons, MT) for Q3-FY26 vs Q3-FY25: - Chlorination: decreased from 380 MT to 362 MT - Hydrogenation: decreased from 286 MT to 258 MT - Ammonolysis: steady around 93 MT (Q3-FY25: 97 MT) - Others: slight decrease from 97 MT to 93 MT - Revenue breakup Q3-FY26 by chemistry: Chlorination 23%, Hydrogenation 43%, Ammonolysis 28%, Others 6% - Q3-FY26 Consolidated Financials: - EBITDA: INR 156 Mn, up 1.3% YoY from INR 154 Mn.

From Valiant Organics Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3-FY26 Consolidated Revenue from Operations: INR 1,593 Mn, down 14.8% YoY (Q3-FY25: INR 1,869 Mn)
  • Q3-FY26 Standalone Revenue from Operations: INR 1,591 Mn, down 14.9% YoY (Q3-FY25: INR 1,869 Mn)
  • Key chemistry sales volumes (Metric Tons, MT) for Q3-FY26 vs Q3-FY25:
  • Chlorination: decreased from 380 MT to 362 MT
  • Hydrogenation: decreased from 286 MT to 258 MT
  • Ammonolysis: steady around 93 MT (Q3-FY25: 97 MT)
  • Others: slight decrease from 97 MT to 93 MT

2 more points from Valiant Organics Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Valiant Organics Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Valiant Organics Ltd said on order book & pipeline — free account, 30 seconds.

Valiant Organics Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Valiant Organics Ltd Q3 FY26 results — key figures

Valiant Organics Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue159187-15%157+1.3%
Operating profit (EBITDA)1315-13.3%21-38.1%
Operating margin8%8%0 pp13%-5 pp
Profit before tax660%7-14.3%
Net profit (PAT)45-20%6-33.3%
EPS (₹)1.301.98-34.3%2.02-35.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹304 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Neochem Bio (Q3 FY26)

    Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and

  • Thirumalai Chemicals (Q3 FY26)

    Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran

  • IVP (Q3 FY26)

    Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector

  • Gujarat Alkalies (Q3 FY26)

    3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Valiant Organics Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Valiant Organics Ltd Q3 FY26 results?

Q3-FY26 Consolidated Revenue from Operations: INR 1,593 Mn, down 14.8% YoY (Q3-FY25: INR 1,869 Mn) - Q3-FY26 Standalone Revenue from Operations: INR 1,591 Mn, down 14.9% YoY (Q3-FY25: INR 1,869 Mn) - Key chemistry sales volumes (Metric Tons, MT) for Q3-FY26 vs Q3-FY25: - Chlorination: decreased from 380 MT to 362 MT - Hydrogenation: decreased from 286 MT to 258 MT - Ammonolysis: steady around 93 MT (Q3-FY25: 97 MT) - Others: slight decrease from 97 MT to 93 MT - Revenue breakup Q3-FY26 by chemistry: Chlorination 23%, Hydrogenation 43%, Ammonolysis 28%, Others 6% - Q3-FY26 Consolidated Financials: - EBITDA: INR 156 Mn, up 1.3% YoY from INR 154 Mn.

What is Valiant Organics Ltd share price analysis?

Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.